Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: Results of an open randomized trial at a University hospital

Japanese Journal of Clinical Oncology

Volumn 40, Issue 8, 2010, Pages 761-767

  Oztoprak, Nefise ^a   Piskin, Nihal ^a   Aydemir, Hande ^a   Celebi, Guven ^a   Akduman, Deniz ^a   Keskin, Aysegul Seremet ^a   Gokmen, Ayla ^a   Engin, Huseyin ^b   Ankarali, Handan ^c  

^a Zonguldak Karaelmas University School of Medicine   (Turkey)

^b Zonguldak Karaelmas Universitesi Tip Fakultesi   (Turkey)

^c DUZCE UNIVERSITY   (Turkey)

Author keywords

Carbapenem; Empirical therapy; Febrile neutropenia; Granulocytopenia; Mortality; Piperacillin tazobactam

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ANTIHISTAMINIC AGENT; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HERPES VIRUS INFECTION; HUMAN; INFECTION; INFECTIOUS ARTHRITIS; KIDNEY FUNCTION; LIVER TOXICITY; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MONOTHERAPY; MORTALITY; MYCOSIS; OROPHARYNX CANDIDIASIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEIZURE; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; CARBAPENEMS; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; NEUTROPENIA; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 77955265400     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq046     Document Type: Article

References (27)

1. Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Supportive Care Therapy 2003;1:23-35.
2. Sanz MA, López J, Lahuerta JJ, Rovira M, Batlle M, Pérez C, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in hematology patients with febrile neutropenia: results of an open randomized, multicentre trial. J Antimicrob Chemother 2002;50:79-88.
3. Sharma A, Lokeshwar N. Febrile neutropenia in haematological malignancies. J Postgrad Med 2005;51:42-8.
4. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006;57:176-89.
5. Yildirim I, Aytac S, Ceyhan M, Cetin M, Tuncer M, Cengiz AB, et al. Piperacillin/tazobactam plus amikacin versus carbapenem monotherapy as empirical treatment of febrile neutropenia in child hood hematological malignancies. Pediatr Hematol Oncol 2008;25: 291-9.
6. Elting LS, Rubenstein EB, Rolston KVI. Outcomes of bacteremia in patients with cancer and neutropenia:observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25: 247-59.
7. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982;72:101-11.
8. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
9. Cometta A, Glauser MP. Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review. J Chemother 1996;8:375-81.
10. Hamidah A, Rizal AM, Nordiah AJ, Jamal R. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients. Singapore Med J 2008;49:26-30.
11. Cometta A, Calandra T, Gaya H, Zinner SH, de Bock R, Del Favero A, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malttie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother 1996;40:1108-15.
12. Hung KC, Chiu HH, Tseng YC, Wang JH, Lin HC, Tsai FJ, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy. J Microbiol Immunol Infect 2003;36:254-9.
13. Norrby SR. Carbapenems. Med Clin North Am 1995;79:745-59.
14. Marra F, Reynolds R, Stiver G, Bryce E, Sleigh K, Frighetto L, et al. Piperacillin/tazobactam versus imipenem: a double-blind, randomized fomulary feasibility study at a major teaching hospital. Diagn Microbiol Infect Dis 1998;31:355-68.
15. Sanz MA, Bermúdez A, Rovira M, Besalduch J, Pascual MJ, Nocea G, et al. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study. Curr Med Res Opin 2005;21:645-55.
16. Serefhanoglu K, Ersoy Y, Serefhanoglu S, Aydogdu I, Kuku I, Kaya E. Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia. Ann Acad Med Singapore 2006;35: 11-6.
17. Leyland MJ, Bayston KF, Cohen J, Warren R, Newland AC, Bint AJ, et al. A comparative study of imipenem versus piperacillin plus gentamycin in the initial management of febrile neutropenic patients. J Antimicrob Chemother 1992;30:843-54.
18. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51.
19. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin Infect Dis 2008;46:1813-21.
20. Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect Dis 2002;2:231-42.
21. Bodey GP, Elting L, Jones P, Alvarez ME, Rolston K, Fainstein V. Imipenem/cilastatin therapy of infections in cancer patients. Cancer 1987;60:255-62.
22. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991;115:849-59.
23. Klastersky JA. Use of imipenem as empirical treatment of febrile neutropenia. Int J Antimicrob Agents. 2003;21:393-402.
24. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995;39:445-52.
25. Del Favero A, Menichetti F, Martino P, Bucaneve G, Micozzi A, Gentile G, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empirical therapy for febrile neutropenia. Clin Infect Dis 2001;33:1295-301.
26. Micozzi A, Nucci M, Venditti M, Gentile G, Girmenia C, Meloni G, et al. Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teikoplaninn in the empirical treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis 1993;12:1-8.
27. Figuera A, Rivero N, Pajuelo F, Font P, Leyra F, de La Cámara R, et al. Initial empiric therapy of febrile neutropenia with antibiotic monotherapy. Piperacillin/tazobactam versus imipenem/cilastatin (1994-1996). Med Clin (Barc) 2001;116:610-1.